Matinas BioPharma reduces quorum threshold, adds change-in-control bonuses for CEO/CFO, schedules annual meeting

Matinas BioPharma Holdings, Inc.

Board reduced stockholder quorum from majority to one-third of voting power to facilitate meetings.
CEO Jerome Jabbour eligible for retention bonus up to $299,000 if change in control occurs before March 31, 2026.
CFO Keith Kucinski eligible for retention bonus up to $166,400 under same change-in-control terms.
2025 annual meeting set for June 23, 2025; record date May 1, 2025.
Stockholder proposals and nominations must be received by May 12, 2025.

item 3.03 item 5.02 item 5.08 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.